David Sallman
大卫·萨尔曼
MD
Assistant Member, Department of Malignant Hematology恶性血液病科助理成员
👥Biography 个人简介
David Sallman is an emerging leader in MDS research focusing on novel immunotherapeutic and p53-targeting strategies. He has led trials of magrolimab (CD47 inhibitor) and eprenetapopt (APR-246) in TP53-mutated MDS and AML, addressing a high-risk subgroup with poor prognosis.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CD47/Magrolimab in MDS
Led pivotal early-phase trials of magrolimab combined with azacitidine in MDS and AML, demonstrating promising responses in TP53-mutated disease and advancing CD47-targeted immunotherapy.
APR-246/Eprenetapopt in TP53 MDS
Conducted key trials of eprenetapopt (APR-246) targeting mutant p53 in MDS, providing proof-of-concept for p53 reactivation as a therapeutic strategy in this aggressive subtype.
Representative Works 代表性著作
Magrolimab plus Azacitidine in TP53-Mutant MDS and AML
Journal of Clinical Oncology (2023)
Demonstrated encouraging response rates for magrolimab–azacitidine in TP53-mutated MDS/AML, validating CD47 blockade as a novel therapeutic target in this high-risk subset.
Eprenetapopt plus Azacitidine in TP53-Mutated MDS
Journal of Clinical Oncology (2021)
Phase II trial showing eprenetapopt plus azacitidine achieved CR rates of 33% in TP53-mutated MDS, supporting the concept of mutant-p53 reactivation therapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 大卫·萨尔曼 的研究动态
Follow David Sallman's research updates
留下邮箱，当我们发布与 David Sallman（Moffitt Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment